Alzinova AB (publ) (ALZ.ST)
SEK 3.5
(0.0%)
SEK 3.5
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -3.27 Million SEK | -151.64% |
| 2022 | -1.3 Million SEK | -7.79% |
| 2021 | -1.2 Million SEK | -135.56% |
| 2020 | -513.04 Thousand SEK | -36.67% |
| 2019 | -375.38 Thousand SEK | 25.5% |
| 2018 | -503.89 Thousand SEK | 29.99% |
| 2017 | -719.72 Thousand SEK | -619.73% |
| 2016 | -99.99 Thousand SEK | 82.27% |
| 2015 | -564 Thousand SEK | -56401000.0% |
| 2014 | 1.00 SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - SEK | 100.0% |
| 2024 Q2 | -3.81 Million SEK | 0.0% |
| 2023 Q2 | -1.18 Million SEK | 16.76% |
| 2023 Q3 | -1.15 Million SEK | 2.92% |
| 2023 Q4 | -3.27 Million SEK | -184.55% |
| 2023 FY | -3.27 Million SEK | -151.64% |
| 2023 Q1 | -1.42 Million SEK | -9.43% |
| 2022 FY | -1.3 Million SEK | -7.79% |
| 2022 Q4 | -1.3 Million SEK | -8.23% |
| 2022 Q1 | -1.82 Million SEK | -50.75% |
| 2022 Q2 | -1.51 Million SEK | 16.9% |
| 2022 Q3 | -1.2 Million SEK | 20.5% |
| 2021 FY | -1.2 Million SEK | -135.56% |
| 2021 Q3 | -850.24 Thousand SEK | 11.71% |
| 2021 Q2 | -962.97 Thousand SEK | -218.94% |
| 2021 Q4 | -1.2 Million SEK | -42.14% |
| 2021 Q1 | -301.93 Thousand SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 FY | -513.04 Thousand SEK | -36.67% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | -375.38 Thousand SEK | 25.5% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | -503.89 Thousand SEK | 29.99% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 FY | -719.72 Thousand SEK | -619.73% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 FY | -99.99 Thousand SEK | 82.27% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 FY | -564 Thousand SEK | -56401000.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2014 FY | 1.00 SEK | 0.0% |
| 2014 Q4 | 1.00 SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | 163900050.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 21.747% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | - SEK | Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 54.064% |
| Mendus AB (publ) | - SEK | Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 121.993% |
| Intervacc AB (publ) | 10.48 Million SEK | 131.27% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | -131019.96% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 109.305% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 136.149% |
| Aptahem AB (publ) | - SEK | Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | Infinity% |
| Kancera AB (publ) | -1950.00 SEK | -168002.513% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 204.063% |
| Saniona AB (publ) | 1.00 SEK | 327800000.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | -101.599% |
| Biovica International AB (publ) | 2.19 Million SEK | 249.068% |
| Spago Nanomedical AB (publ) | 1.00 SEK | 327800000.0% |
| AcouSort AB (publ) | 2.08 Million SEK | 257.596% |
| Xintela AB (publ) | 398 Thousand SEK | 923.618% |
| Abliva AB (publ) | - SEK | Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 568.286% |
| Karolinska Development AB (publ) | - SEK | Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | -279.838% |
| Amniotics AB (publ) | 534 Thousand SEK | 713.857% |
| 2cureX AB (publ) | -1000.00 SEK | -327699.9% |
| CombiGene AB (publ) | -1.79 Million SEK | -82.212% |
| Asarina Pharma AB (publ) | - SEK | Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 116.047% |
| Camurus AB (publ) | 100.95 Million SEK | 103.247% |
| Corline Biomedical AB | -3.85 Million SEK | 15.012% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | 327899.9% |
| Isofol Medical AB (publ) | - SEK | Infinity% |
| I-Tech AB | 4.28 Million SEK | 176.589% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 133.476% |
| Cyxone AB (publ) | - SEK | Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | Infinity% |
| Biosergen AB | -4.92 Million SEK | 33.496% |
| Cantargia AB (publ) | - SEK | Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | 701.206% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 107.487% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | -633.356% |
| Nanologica AB (publ) | 2.97 Million SEK | 210.259% |
| SynAct Pharma AB | - SEK | Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | -920.722% |
| LIDDS AB (publ) | - SEK | Infinity% |
| Lipum AB (publ) | - SEK | Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 127.676% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 235.175% |
| Pila Pharma AB (publ) | 1.00 SEK | 327800000.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | -220492.127% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 181.259% |
| Simris Alg AB (publ) | 1.09 Million SEK | 400.458% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 113.63% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 103.068% |
| Ascelia Pharma AB (publ) | - SEK | Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 418.871% |